• Published on: Jul 22, 2020
  • 2 minute read
  • By: Dr Rajan Choudhary

The Oxford Vaccine

  • WhatsApp share link icon
  • copy & share link icon
  • twitter share link icon
  • facebook share link icon

Recently we wrote a blog on the success of an RNA vaccine against SARS-CoV-2, the virus responsible for COVID-19. Within just a few weeks of that incredible research breakthrough, researchers at Oxford University’s Jenner Institute have announced a COVID vaccine that has induced remarkable immune response against the virus.

This study was published in the Lancet, one of the most prestigious medical journals in the world, and a simple summary suggests the vaccine has no early safety concern and is able to induce a strong immune response with both T cells and B cell/antibodies.

THE VACCINE

ChAdOx1 nCoV-19, now known as AZD1222, was co-developed by the University of Oxford and one of its spin-off companies, Vaccitech. The vaccine uses a viral vector based on a common cold virus (adenovirus). This carries genetic material for the SARS-CoV-2 spike protein. In our previous blog, we saw how the spike proteins are used by the virus to target and fuse with our target cells, allowing the virus to invade, replicate and ultimately cause the disease known as COVID. It is also a good target for the human immune system to recognize and attack.

The viral vector delivers the genetic material inside our cells. The spike protein is then produced by our cells, recognized by the immune system as a viral target, and an immune response is created against it. This can be antibodies, which recognize, attach to and mark the virus in our blood, allowing for other white blood cells to destroy the virus.

In this case, the vaccine also produced a T cell response. T cells can recognize cells infected by a virus-based on the markers present on the surface of infected cells. They can tell an infected cell to destroy itself, thereby destroying the virus within without spreading the infection. They also have other functions that we will not discuss in this blog.

THE STUDY

This study was a Phase I/II trial that started in April using the vaccine named ChAdOx1 nCoV-19. This vaccine development started in January 2020, and progress on development has been incredibly rapid. Whilst our previous study had just 45 people, this study looked reviewed over 1,000 healthy adults. 10 of these participants received two doses of the vaccine.

In a study the more participants there are, the greater the power of the study. If the vaccine has any side effects, even ones that rarely occur, it is more likely to be picked up in studies with more people. Similarly having more people helps show that the vaccine is effective, and the strong responses are not merely a fluke or accident. Another benefit of this study is it was able to compare the vaccine against a control group. This shows the results were not simply a placebo and allowed comparison of side effects as well.

The majority of side effects were feeling feverish, chills, muscle ache, headache, and malaise, all symptoms treatable with paracetamol. None of the participants had any serious side effects. It took just 14 days to create a T cell response, and  28 days to make strong antibodies. In 91% of patients, this was enough to neutralize the COVID coronavirus. Receiving two doses gave an even stronger antibody response, and all participants were able to stop the virus.

 

WHAT NEXT

The news from the University of Oxford is needed, as infection rate and mortality continue to increase in countries such as the US and Brazil. The ability to induce an antibody response without causing harm to the patient shows we have made huge progress in the fight against COVID-19. Further Large scale Phase III trials been set up through a global partnership, and include studies in the US with over 30,000 patients, studies in children as well as some in low to middle-income countries.

If successful a vaccine would be essential in preventing a second wave of COVID in the winter when the elderly population is most at risk. And it would be the key to restarting the economy and getting our everyday lives back to where it was pre-pandemic.

Read Blog
Tuberculosis

Tuberculosis Symptoms and Treatment: Early Signs, Diagnosis, and Recovery

Tuberculosis (TB) is one of the oldest known infectious diseases and continues to be a major public health concern, especially in developing countries. India accounts for a significant proportion of global TB cases, despite advances in diagnosis and treatment. The good news is that tuberculosis is preventable, treatable and curable when detected early and managed properly.

Understanding tuberculosis symptoms and treatment is critical for reducing disease spread, preventing complications and achieving complete recovery.

 

What Is Tuberculosis?

Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis. It primarily affects the lungs (pulmonary TB) but can also involve other parts of the body such as:

  • lymph nodes
     

  • bones and joints
     

  • kidneys
     

  • brain
     

TB spreads through the air when an infected person coughs, sneezes or speaks.

 

Why Tuberculosis Remains a Major Health Issue

According to the World Health Organization and ICMR data:

  • millions of new TB cases are reported annually
     

  • delayed diagnosis increases transmission
     

  • incomplete treatment leads to drug resistance
     

Early detection and treatment are key to TB control.

 

Common Tuberculosis Symptoms

TB symptoms often develop gradually and may be mild in the early stages, leading to delayed diagnosis.

Persistent Cough

A cough lasting more than two to three weeks is a hallmark symptom of pulmonary TB.

The cough may:

  • be dry or productive
     

  • worsen over time
     

  • sometimes produce blood
     

 

Fever and Night Sweats

Low-grade fever, especially in the evenings, is common.

Night sweats that soak clothing or bedding are a classic TB sign.

 

Unexplained Weight Loss

TB increases metabolic demand and reduces appetite, leading to significant weight loss.

 

Fatigue and Weakness

Persistent tiredness and reduced stamina occur due to chronic infection.

 

Chest Pain

Chest discomfort or pain may occur during coughing or breathing.

 

Symptoms of Extra-Pulmonary TB

When TB affects organs outside the lungs, symptoms depend on the site involved and may include:

  • swollen lymph nodes
     

  • bone or joint pain
     

  • headaches or neurological symptoms
     

  • urinary issues
     

 

Why TB Symptoms Are Often Ignored

Many TB symptoms resemble common infections or general weakness.

This leads to:

  • delayed medical consultation
     

  • prolonged transmission
     

  • disease progression
     

Awareness improves early detection.

 

How Tuberculosis Is Diagnosed

Diagnosis involves a combination of:

  • sputum tests
     

  • chest X-ray
     

  • molecular tests such as CBNAAT
     

  • blood tests and imaging for extra-pulmonary TB
     

Early and accurate diagnosis is essential for effective treatment.

 

Tuberculosis Treatment Explained

TB treatment involves a combination of antibiotics taken over a fixed duration.

Standard TB Treatment

For drug-sensitive TB, treatment typically lasts:

  • 6 months
     

The regimen includes multiple antibiotics taken in phases to ensure complete bacterial clearance.

 

Importance of Treatment Adherence

TB bacteria are slow-growing and resilient.

Stopping treatment early can result in:

  • incomplete cure
     

  • relapse
     

  • drug-resistant TB
     

Completing the full course is essential.

 

Drug-Resistant TB

If TB bacteria become resistant to standard drugs, treatment becomes longer and more complex.

Drug-resistant TB requires:

  • specialised medications
     

  • longer treatment duration
     

  • close medical supervision
     

Prevention of resistance depends on correct treatment from the start.

 

Side Effects of TB Treatment

Some individuals may experience side effects such as:

  • nausea
     

  • loss of appetite
     

  • mild liver enzyme changes
     

Most side effects are manageable with medical guidance and do not require stopping treatment.

 

TB and Public Health

TB is not just an individual health issue but a community concern.

Effective TB control requires:

  • early diagnosis
     

  • treatment adherence
     

  • contact tracing
     

  • public awareness
     

India’s national TB elimination programmes focus on these strategies.

 

Preventing Tuberculosis

Preventive measures include:

  • early detection and treatment of active TB
     

  • improving nutrition and immunity
     

  • adequate ventilation in living spaces
     

  • screening close contacts
     

BCG vaccination offers partial protection, especially in children.

 

Living With and Recovering From TB

With proper treatment:

  • symptoms gradually improve
     

  • infection becomes non-contagious
     

  • normal life can be resumed
     

Regular follow-up ensures complete recovery.

 

When to Seek Medical Help

Consult a healthcare provider if experiencing:

  • cough lasting more than two weeks
     

  • unexplained weight loss
     

  • persistent fever or night sweats
     

  • blood in sputum
     

Early action saves lives and prevents spread.

 

Long-Term Outlook After TB Treatment

Most individuals who complete treatment:

  • recover fully
     

  • regain normal lung function
     

  • return to daily activities
     

Long-term complications are rare with timely care.

 

Conclusion

Tuberculosis symptoms and treatment must be understood clearly to combat this preventable and curable disease. Persistent cough, fever, night sweats and weight loss should never be ignored. Early diagnosis, complete treatment adherence and regular follow-up are essential for curing TB and preventing transmission. With proper medical care and public awareness, tuberculosis can be effectively controlled and eliminated as a public health threat.


 

References

  • Indian Council of Medical Research (ICMR) – Tuberculosis Epidemiology and Treatment Guidelines
  • World Health Organization (WHO) – Global Tuberculosis Report
  • National Tuberculosis Elimination Programme (NTEP) – Government of India
  • Lancet Infectious Diseases – TB Diagnosis and Treatment Outcomes
  • National Family Health Survey (NFHS-5) – Infectious Disease Indicators
  • Statista – Global Tuberculosis Burden and Trends

See all

Live Doctor consultation
Live Doctor Chat

Download Our App & Get Consultation from anywhere.

App Download
call icon for mobile number calling and whatsapp at secondmedic